肿瘤免疫治疗性抗体功能鉴定与分析平台

 

金斯瑞成功开发并验证了靶向不同免疫细胞(NK细胞、T细胞、巨噬细胞)和补体系统的抗体药物活性鉴定与评价方法和技术,包括ADCC、CDC、ADCP、Phagocytosis、T细胞增激活与抑制分析等,涉及的靶点包括CD20、 EGFR、HER2、tm-TNFa、PD-1/PD-L1、CTLA-4、OX-40、TIM-3、 LAG-3、CD40、4-1BB、B7-H3、TIGIT、GITR及CD47等。

服务内容

    NK细胞
    T细胞
    巨噬细胞
    补体系统
    作用机理
    Antibody-Dependent Cell-mediated Cytotoxicity (ADCC)
    T cell Activation/Inhibition
    Antibody-Dependent Cellular Phagocytosis (ADCP), Phagocytosis
    Complement Dependent Cytotoxicity (CDC)
    已开发的靶点
    CD20, EGFR, HER2, tm-TNFa
    PD-1/PD-L1, CTLA-4, OX-40 NEW
    CD20, HER2,
    CD47 NEW
    CD20, tm-TNFa
    方法学
    PBMC, NK cells, Engineered NK cells,
    IL-2 release
    Mixed-Lymphocyte Reaction (MLR),
    Reporter gene assays
    FACS
    Cell lysis detection

同时,我们开发了全球最大的Immuno-Oncology相关靶点过表达稳定细胞株库,主要用于细胞免疫、亲和力分析、交叉反应及功能分析等。

    Developed Immuno-Oncology Cell Lines
    Target
    Cell Line
    Target
    Cell Line
    4-1BB
    CHO-K1/human 4-1BB
    PD-1
    CHO-K1/human PD-1
    CHO-K1/mouse 4-1BB CHO-K1/mouse PD-1
    CHO-K1/cyno 4-1BB CHO-K1/cyno PD-1
    B7-H3
    CHO-K1/human B7-H3
    PD-L1
    CHO-K1/human PD-L1
    B7-H4
    CHO-K1/human B7-H4 HEK293/human PD-L1
    BTLA
    CHO-K1/human BTLA CHO-K1/mouse PD-L1
    CD160
    CHO-K1/human CD160 CHO-K1/cyno PD-L1
    CD200 R1
    CHO-K1/human CD200 R1
    TIGIT
    CHO-K1/human TIGIT
    CD40
    CHO-K1/human CD40
    Tim3
    CHO-K1/human Tim3
    CD80
    CHO-K1/human CD80
    VISTA
    CHO-K1/human VISTA
    CD86
    CHO-K1/human CD86
    FLT3
    CHO-K1/human FLT3
    CTLA4
    CHO-K1/human CTLA4 CHO-K1/human FLT3 mutant
    CHO-K1/mouse CTLA4 CHO-K1/mouse FLT3
    CHO-K1/cyno CTLA4 CHO-K1/cyno FLT3
    GITR
    CHO-K1/human GITR
    CD38
    CHO-K1/human CD38
    Lag3
    CHO-K1/human Lag3
    CD27
    CHO-K1/human CD27
    OX-40L
    CHO-K1/human OX-40L
    OX-40
    CHO-K1/human OX-40
    mTNFα
    CHO-DG44/mTNFα
    Jurkat/mTNFα

询价与订购

客服